二肽基肽酶Ⅳ抑制剂在Ⅱ型糖尿病大鼠中的降糖作用的比较
Compare with antihyperglycemic effects of dipeptidyl peptidase 4 inhibitors in type Ⅱ diabetic rats
作者：侯君;李聃丹;王维维;周世文;
Author：
收稿日期： 年卷（期）页码：2013,28(04):-360-363
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：二肽基肽酶Ⅳ;Ⅱ型糖尿病;西格列汀;维格列汀;沙格列汀
Key words：
基金项目：重庆市自然科学基金(编号:CSTC2009BA5012)
中文摘要
目的探讨二肽基肽酶Ⅳ(DPP4)抑制剂西格列汀、维格列汀、沙格列汀降糖作用的高低。方法采用高脂饲料喂养加ip小剂量链脲佐菌素建立Ⅱ型糖尿病大鼠模型。将大鼠随机分为对照组、模型组、西格列汀、维格列汀、沙格列汀组,Gly-Pro-AMC荧光底物法测定体内外DPP4抑制率,放免法测定血浆胰岛素浓度,ELISA测定血浆GLP-1浓度。结果西格列汀在体外抑制DPP4的活性高于维格列汀和沙格列汀。与模型组比较,DPP4抑制剂各组均能明显降低血糖水平(P
参考文献
[1]Doupis J,Veves A.DPP4 inhibitors:A new approach in diabetestreatment[J].Adv Ther,2008,25:627-643.
[2]Borja-Hart NL,Whalen KL.Saxagliptin:A new dipeptidyl pep-tidase 4 inhibitor for type 2 diabetes[J].Ann Pharmacother,2010,44:1046-1053.
[3]Dalla Man C,Bock G,Giesler PD,et al.Dipeptidyl peptidase-4inhibition by vildagliptin and the effect on insulin secretion andaction in response to meal ingestion in type 2 diabetes[J].Dia-betes Care,2009,32:14-18.
[4]Deacon CF,Holst JJ.Saxagliptin:A new dipeptidyl peptidase-4inhibitor for the treatment of type 2 diabetes[J].Adv Ther,2009,26:488-499.
[5]Hou J,Zheng DZ,Zhou JY,et al.Orexigenic effect of cocaine-and amphetamine-regulated transcript(CART)after injectioninto hypothalamic nuclei in streptozotocin-diabetic rats[J].ClinExp Pharmacol P,2010,37:989-995.
[6]Lee B,Shi L,Kassel DB,et al.Pharmacokinetic,pharmacodyna-mic,and efficacy profiles of alogliptin,a novel inhibitor of dipep-tidyl peptidase-4,in rats,dogs,and monkeys[J].Eur J Phar-macol,2008,589:306-314.
[7]Bolen S,Feldman L,Vassy J,et al.Systematic review:compara-tive effectiveness and safety of oral medications for type 2 diabetesmellitus[J].Ann Intern Med,2007,147:386-399.
[8]Camp HS.Thiazolidinediones in diabetes:current status andfuture outlook[J].Curr Opin Investig Drugs,2003,4:406-411.
[9]DeFronzo RA.Pharmacologic therapy for type 2 diabetes mellitus[J].Ann Intern Med,1999,131:281-303.
[10]Stades AM,Heikens JT,Erkelens DW,et al.Metformin and lacticacidosis:cause or coincidence?A review of case reports[J].JIntern Med,2004,255:179-187.
[11]Singh SK,Manne N,Pal M.Synthesis of(S)-1-(2-chloro-acetyl)pyrrolidine-2-carbonitrile:A key intermediate fordipeptidyl peptidase IV inhibitors[J].Beilstein J Org Chem,2008,4:20.
[12]Tsai TY,Hsu T,Chen CT,et al.Rational design and synthesis ofpotent and long-lasting glutamic acid-based dipeptidyl pepti-daseⅣinhibitors[J].Bioorg Med Chem Lett,2009,19:1908-1912.
[13]White PC,Chamberlain-Shea H,de la Morena MT.Sitagliptintreatment of patients with type 2 diabetes does not affect CD4+T-cell activation[J].J Diabetes Complications,2010,24:209-213.
【关闭】
